Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy

被引：0
|
作者：
Luo, F. [1 ]
Liu, Y. Y. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; liver dysfunction; hepatopathy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-73
引用
收藏
页码：S671 / S672
页数：2
相关论文
共 50 条
  • [1] Efficacy of Chemotherapy after First-Line Gefitinib for EGFR-Mutant NSCLC Patients
    Kuwako, Tomohito
    Imai, Hisao
    Masuda, Tomomi
    Miura, Yosuke
    Yoshino, Reiko
    Kaira, Kyoichi
    Shimizu, Kimihiro
    Sunaga, Noriaki
    Tomizawa, Yoshio
    Ishihara, Shinichi
    Mogi, Akira
    Hisada, Takeshi
    Minato, Koichi
    Takise, Atsushi
    Saito, Ryusei
    Yamada, Masanobu
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S646
  • [2] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [3] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [5] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [6] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [7] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
    Sabari, J. K.
    Yu, H. A.
    Mahadevia, P.
    Liu, Y.
    Demirdjian, L.
    Sultan, A. A.
    Chen, Y. H.
    Wang, X.
    Passaro, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
  • [8] EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Moore, Sara
    Wheatley-Price, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1788 - 1792
  • [9] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [10] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
12345